Abstracts tagged "Late-Breaking 2019"

Abstract Number: L17 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Eric Morand¹, Richard Furie ², Yoshiya Tanaka ³, Ian Bruce ⁴, Anca Askanase ⁵, Christophe Richez ⁶, Sang-Cheol Bae ⁷, Philip Brohawn ⁸, Lilia Pineda ⁹, Anna Berglind ¹⁰ and Raj Tummala ⁹, ¹Monash University, Melbourne, Victoria, Australia, ²Zucker School of Medicine at Hofstra/Northwell, New York, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁵Columbia University, New York, ⁶CHU de Bordeaux-GH Pellegrin, Bordeaux, France, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Former employee of AstraZeneca, Gaithersburg, Maryland, ⁹AstraZeneca, Gaithersburg, Maryland, ¹⁰AstraZeneca, Gothenburg, Sweden
Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Naizhuo Zhao ¹, Audrey Smargiassi ², Marianne Hatzopoulou ³, Ines Colmegna ⁴, Marie Hudson ⁵, Marvin Fritzler ⁶, Philip Awadalla ⁷ and Sasha Bernatsky⁸, ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²University of Montreal, Montreal, Canada, ³University of Toronto, Toronto, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁷Ontario Institute for Cancer Research, Toronto, Canada, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
Abstract Number: L18 • 2019 ACR/ARP Annual Meeting
A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study
Di Wu¹, Jing Li ², Dong Xu ², Wenxiang Wang ³, Lin Li ⁴, Jianmin Fang ³ and Fengchun Zhang ⁵, ¹Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ²Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Beijing, China (People's Republic), ³RemeGen, Ltd., Yantai, China (People's Republic), ⁴RemeGen, Ltd., Beijing, China (People's Republic), ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Telitacicept, also named RC18, is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and…
Abstract Number: L03 • 2019 ACR/ARP Annual Meeting
NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia
Steven Harte ¹, Leslie Arnold ², Eric Ichesco ¹, Christopher Crumb ¹, Mary Suh ³, Laurel Sindelar ³, Chelsea Kaplan ¹, Tony Larkin ¹, Andrew Schrepf ¹, Daniel Clauw ⁴, Stephen Sainati ³ and Richard Harris¹, ¹University of Michigan, Ann Arbor, ²University of Cincinnati College of Medicine, Cincinnati, ³Aptinyx Inc, Evanston, ⁴Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Fibromyalgia (FM) is a chronic, debilitating disease typified by widespread musculoskeletal pain and accompanied by fatigue, sleep disturbance, memory issues, and mood disorders. FM…
Abstract Number: L19 • 2019 ACR/ARP Annual Meeting
Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
Simon Bowman¹, Robert Fox ², Thomas Dörner ³, Xavier Mariette ⁴, Athena Papas ⁵, Thomas Grader-Beck ⁶, Benjamin A. Fisher ⁷, Filipe Barcelos ⁸, Salvatore De Vita ⁹, Hendrik Schulze-Koops ¹⁰, Robert J. Moots ¹¹, Guido Junge ¹², Janice Woznicki ¹³, Monika Sopala ¹², Wen-Lin Luo ¹³ and Wolfgang Hueber ¹², ¹University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ²Scripps Memorial Hospital and Research Institute, La Jolla, California, ³Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Tufts School of Dental Medicine, Massachusetts, ⁶Johns Hopkins University, Baltimore, ⁷University Hospitals Birmingham NHS Foundation Trust, Birmingham Biomedical Research Centre, Birmingham, United Kingdom, ⁸Nova Medical School, Hospital Cuf Descobertas, Instituto Português de Reumatologia,, Lisbon, Portugal, ⁹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ¹⁰Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ¹¹Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ¹²Novartis Pharma AG, basel, Switzerland, ¹³Novartis Pharmaceuticals Corporation, New Jersey
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…
Abstract Number: L04 • 2019 ACR/ARP Annual Meeting
Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease
Maaman Bashir¹, Katherine Sherman ², Sara K. Tedeschi ³ and Ann Rosenthal ¹, ¹Medical College of Wisconsin, Milwaukee, ²Milwaukee VAMC, Milwaukee, ³Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from precipitation of calcium pyrophosphate (CPP) crystals in joints. Prior studies demonstrated that vascular calcification is more common…
Abstract Number: L20 • 2019 ACR/ARP Annual Meeting
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Josef Smolen¹, Peter Nash ², Hasan Tahir ³, Hendrik Schulze-Koops ⁴, Lingnan Li ⁵, Maja Hojnik ⁶, Amanda Gellett ⁵, Soyi Liu-Leage ⁷, Sreekumar Pillai ⁷ and Philip J. Mease ⁸, ¹Medical University of Vienna, Vienna, Austria, ²Griffith University, Brisbane, Queensland, Australia, ³Royal Free London NHS Trust, London, United Kingdom, ⁴Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ⁵Eli Lilly and Company, Indianapolis, Indiana, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Swedish Medical Center and University of Washington, Seattle, Washington
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].